Standardization of Minimal Residual Disease Testing in Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Minimal residual disease in multiple myeloma.
Multiple myeloma (MM) is a B-cell malignancy in which abnormal, clonal plasma cells proliferate and accumulate in the bone marrow. These abnormal cells, referred to as myeloma cells, disrupt normal bone marrow function and invade bone. Myeloma cells produce and secrete significant quantities of monoclonal protein (M-protein) into the blood and/or urine.1 The clinical features of MM include hype...
متن کاملMinimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients. The integration of the next generation of proteasome inhibitors and antibody therapeutics promise continued improvements in therapy with the expectation of consistent depth of respon...
متن کاملThe prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma
and San Miguel JF. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma. Publisher's Disclaimer.0 E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have be...
متن کاملNew criteria for response assessment: role of minimal residual disease in multiple myeloma.
Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma (MM), the majority of patients will inevitably relapse despite achievement of progressively higher complete remission (CR) rates. Novel treatment protocols with inclusion of antibodies and small molecules might well be able...
متن کاملWhole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease.
Multiple myeloma is a plasma cell dyscrasia. It is the second most common hematological malignancy which is characterized by proliferation of clonal plasma cells producing harmful monoclonal immunoglobulin. Despite treatment modalities greatly evolved during the last decade, small amount of aberrant residual cells reside in patients after therapy and can cause relapse of the disease. Characteri...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Applied Laboratory Medicine: An AACC Publication
سال: 2017
ISSN: 2475-7241
DOI: 10.1373/jalm.2016.020883